Primary aldosteronism in AF patients: To screen or not to screen?

Abstract

Get full access to this article

View all access options for this article.

References

Andersson

Magnuson

Bryngelsson

et al.

All-cause mortality in 272 186 patients hospitalized with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term case–control study. Eur Heart J 2013; 34: 1061–1067.

Stewart

Hart

Hole

et al.

A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359–364.

Mourtzinis

Eryd

Rosengren

et al.

Primary aldosteronism and thyroid disorders in atrial fibrillation: a Swedish nationwide case–control study. Eur J Prev Cardiol 2018. in press.

Struthers

. Aldosterone: cardiovascular assault. Am Heart J 2002; 144: S2–S7.

Reil

Hohl

Selejan

et al.

Aldosterone promotes atrial fibrillation. Eur Heart J 2012; 33: 2098–2108.

Klein

Ojamaa

. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501–509.

Lammers

Dartsch

Brandt

et al.

Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat. Cell Physiol Biochem 2012; 29: 833–840.

Gorenek

Pelliccia

Benjamin

et al.

European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Eur J Prev Cardiol 2017; 24: 4–40.

Mourtzinis

Schiöler

Kahan

et al.

Antihypertensive control and new-onset atrial fibrillation: results from the Swedish Primary Care Cardiovascular Database (SPCCD). Eur J Prev Cardiol 2017; 24: 1206–1211.

10.

Hylek

Phillips

et al.

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370–2375.

11.

Wolf-Maier

Cooper

Banegas

et al.

Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363–2369.

12.

Healey

Connolly

. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol 2003; 91: 9G–14G.

13.

Frost

Vestergaard

Mosekilde

. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 2004; 164: 1675–1678.